

BIOLOGICS


Spotlight On: Trastuzumab




February 28, 2025


















Technology: Trastuzumab is a humanized monoclonal antibody that targets the HER2/neu receptor, which is overexpressed in some types of cancer. The HER2 pathway is involved in cell growth and division.

	Genentech v. Pfizer 1:17-cv- 01672 (D. Del.) Settled Cont'd below	Celltrion v. Genentech 4:18-cv- 00274 (N.D. Cal.) Dismissed; Fed. Cir. 18- 2160 Dismissed Cont'd below	Genentech v. Celltrion 1:18-cv- 00095 (D. Del.) Settled Cont'd below	Genentech v. Amgen 1:18-cv- 00924 (D. Del.) Settled; Fed. Cir. 19- 2156 TRO/PI Denied Cont'd below	Genentech v. Celltrion 1:18-cv- 01025 (D. Del.) Settled Cont'd below	Genentech v. Samsung Bioepis 1:18-cv- 01363 (D. Del.) Settled Cont'd below	Pfizer v. Genentech IPR2017-02019 Settled after institution; IPR2018-00330 Institution and joinder denied	Celltrion v. Genentech IPR2017-01373 IPR2017-01374 FWD- Some claims unpatentable	Pfizer & Samsung Bioepis v. Genentech IPR2017-01488 IPR2017-02139 (joined) FWD- Some claims unpatentable	Pfizer & Samsung Bioepis v. Genentech IPR2017-01489 IPR2017-02140 (joined) FWD- Some claims unpatentable	Pfizer & Samsung Bioepis v. Genentech IPR2017-00804 IPR2017-01958 (joined) FWD- No claims unpatentable, Fed. Cir. 19-1174 Settled	Celltrion v. Genentech IPR2017-01139 FWD- No claims unpatentable, Fed. Cir. 19- 1258 Settled	Hospira v. Genentech IPR2016-01837 FWD- All claims unpatentable, Fed. Cir. 18- 1933 Affirmed (US as Intervenor, Hospira settled)
6,121,428	Х		Х	Х	Х								
6,242,177	х		х	х	х								
6,331,415	х	х	х	x	х	х							
6,339,142	х	х	х		х	х	х						
6,407,213	x	x	х	х	x	х		х	х	x			
6,417,335	х	x	х	x	х	х	Pfizer &		Hospira v. Genentech	Celltrion & Pfizer v. Genentech IPR2017-01121 IPR2017-02063			
6,489,447	х	х	х	х	x		Samsung Bioepis v.	Genentech IPR2017-01140 FWD- No					
6,586,206	x	x	х	x	x		Genentech						
6,610,516	x	x	x		x	х							
6,620,918	х	х	x	x	x		IPR2017-01959		(Joinea)				
6,627,196	x	x	х	x	x	х	(joined) FWD- No	claims unpatentable,	table, Affirmed (US as	as unpatentable, ed) Fed. Cir. 19- 1267 Affirmed (US as	х	х	
6,716,602	х	x	x		x		claims	Fed. Cir. 19-					
6,870,034				x			unpatentable, Fed. Cir. 19- 1173 Settled	1259 Sottlod	Intervenor, Hospira settled)		<i>Pfizer v.</i> <i>Genentech</i> IPR2018-00016	Samsung Bioepis v. Genentech	Trustees of U of Penn. v. Genentech
7,371,379	х	x	х	x	х	х	х	х		Intervenor,	Institution	IPR2018-00192	1:22-cv-00145
7,390,660	х	х	х		х	x				Other parties settled)	denied	Institution denied	(D. Del.) Ongoing
7,449,184	х	х	х	х	х								
7,485,704	Х	х	Х		Х	х							
7,501,122	х	х	х	х	х								
7,625,558													х
7,807,799	х	х	х		Х	х							
7,846,441	Х	х	Х	х	Х	х			х	х	х	х	

FWD = Final Written Decision





Spotlight On:

Trastuzumab



February 28, 2025

	Genentech v. Pfizer 1:17-cv-01672 (D. Del.) Cont'd from above	Celltrion v. Genentech 4:18-cv-00274 (N.D. Cal.) Cont'd from above	Genentech v. Celltrion 1:18-cv-00095 (D. Del.) Cont'd from above	Genentech v. Amgen 1:18-cv-00924 (D. Del.) Cont'd from above	Genentech v. Celltrion 1:18-cv-01025 (D. Del.) Cont'd from above	Genentech v. Samsung Bioepis 1:18-cv-01363 (D. Del.) Cont'd from above	Genentech v. Tanvex 3:22-cv- 00809 (S.D. Cal.) Settled	Pfizer & Samsung Bioepis v. Genentech IPR2017-00737 IPR2017-01960 (joined) FWD- All claims unpatentable, Fed. Cir. 19-1265 Affirmed (US as Intervenor, Other parties settled)	Pfizer v. Genentech IPR2017-00739 Institution denied	Celltrion v. Genentech IPR2017-01122 FWD- All claims unpatentable, Fed. Cir. 19-1270 Affirmed (US as Intervenor, Celltrion settled)
7,892,549	х	х	х	х	х	х		x	х	Х
7,923,221	х	x	x	х	х	x				
7,993,834	x	x	x	х	х	x				
8,044,017	х			x						
8,076,066	х	х	х	х	х	х				
8,314,225	х			х						
8,357,301		x	х	x	x				Celltrion v.	Pfizer v. Genentech
8,425,908	х	x	х	х	x	х		Pfizer v. Genentech	Genentech IPR2017-00959 Terminated before institution (claims	IPR2017-01726 IPR2017-01727 Institution denied (claims previously cancelled)
8,440,402	х	х	х	х	х	x		IPR2017-02020 Settled after institution;		
8,460,895	х	х	х	х	x			IPR2018-00331 Institution and		
8,512,983	x	х	х	х	х	х		joinder denied		
8,574,869	х	x	x	x	x	x	x		cancelled)	cancenedy
8,591,897									х	Х
8,633,302	х	x	х		x					
8,691,232	x	x	x	x	x					
8,710,196	х			x						
8,771,988	х	x	x	x	х					
8,822,655	х	x	х		x					
9,047,438		x	x	х	x					
9,080,183		x	x	х	х					
9,249,218	х	x	x	x	x	х		x		
9,428,548		x	x		х					
9,428,766	х	x	x	x	x					
9,487,809	x	x	x	х	х					
9,493,744	х			х						
9,714,293	x	x	х	х	х	х				
9,868,760				х						
10,160,811				х						
10,662,237							х			
10,808,037							x			

